Australia-based Propanc Biopharma (NASDAQ: PPCB) said on Monday it has raised up to $100 million from Hexstone Capital, a family office active in Bitcoin, Ethereum, Solana, Dogecoin and other digital assets.
The private placement transaction, structured through convertible preference shares, provides Propanc with an initial investment of $1 million and up to $99 million in follow-on financing over the next year. Proceeds will be used to build Propanc's digital asset portfolio and accelerate the development of its leading oncology therapy, PRP, which currently targets first human trials in 2026.
Chief executive James Nathanierz called the move a "transformation phase" and the company did not specify which digital assets it planned to acquire.
Biotech company Propanc raises $100 million for crypto reserves and cancer therapies
2025-11-10 21:59:39
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
生物科技公司Propanc筹集获1亿美元资金，用于加密储备和癌症疗法研发Next article：
美联储12月降息25个基点的概率为64.1%
